Pearce IP BioBlast w/e 26 Jan 2024
AbbVie announced it will invest US$233M in its biologics manufacturing facility in Singapore. The investment will add 24,000L of biologics…
Source: lexology.com
📰 Genentech Lucentis News
Genentech Lucentis News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Genentech Lucentis. Real-time updates on events, politics, business and more.
FDA Approves Yet Another Interchangeable Biosimilar and Another Biosimilar | McDonnell Boehnen Hulbert & Berghoff LLP
On October 3, 2023, the U.S. Food and Drug Administration (FDA) announced approval of Biogen's Byooviz (ranibizumab-nuna) as an interchangeable biosimilar to Genentech's Lucentis...
Choroidal Neovascularization Genentech Lucentis Genentech Avastin Drug Administration Mcdonnell Boehnen Hulbert Berghoff Mcdonnell Boehnen Hulbert
Source: jdsupra.com
BioBlast w/e 08 Dec 23
The FDA approved Vertex/CRISPR Therapeutics’ Casgevy® and Bluebird Bio’s Lyfgenia®, the first cell-based gene therapies to treat sickle cell disease…
United States United Kingdom Bio Lyfgenia Astrazeneca Merck Lynparza Samsung Bioepi Byooviz Genentech Lucentis
Source: lexology.com
CVS Caremark Switches Up Biosimilar Coverage in 2024
As part of updates to its standard formulary, CVS Caremark has removed Amjevita and now prefers Hyrimoz and an unbranded biosimilar.
Sandoz Ziextenzo Coherus Biosciences Teva Herzuma Genentech Lucentis Amgen Amjevita Biocon Biologics
Source: ajmc.com
New Compound has Potential to Treat Wet AMD Without Injection
Animal studies of a new compound, which can be delivered by eye drop, have found that it can reverse epigenetic changes that lead to wet age-related macular degeneration.
Source: managedhealthcareexecutive.com
Switching Patterns Among Neovascular Age-Related Macular Degeneration: Genentech's Vabysmo Rising, Regeneron's Eylea and Genentech's Off-Label Avastin Remain Strong, According to Spherix Global Insights
/PRNewswire/ -- The switch landscape represents an active segment of the market where brands have the opportunity to capture share. Spherixs RealWorld...
Coherus Bioscience Cimerli Genentech Susvimo Scott Upham Genentech Vabysmo Regeneron Eylea Chrystal Ferguson
Source: prnewswire.com
Implications of Biosimilar Availability in the United States' Ophthalmology Markets Highlighted in New Spherix Global Insights Study
/PRNewswire/ -- Ophthalmologists saw the entry of the first biosimilars into the armamentarium in 2022 with the launch of Biogen and Samsungs Byooviz and...
Coherus Bioscience Cimerli Viatrisa Mylan Scott Upham Regeneron Eylea Chrystal Ferguson Genentech Lucentis
Source: prnewswire.com
Implications of Biosimilar Availability in the United States' Ophthalmology Markets Highlighted in New Spherix Global Insights Study
/PRNewswire/ -- Ophthalmologists saw the entry of the first biosimilars into the armamentarium in 2022 with the launch of Biogen and Samsungs Byooviz and...
Coherus Bioscience Cimerli Viatrisa Mylan Scott Upham Regeneron Eylea Chrystal Ferguson Genentech Lucentis
Source: prnewswire.com
Off-Label Avastin (Genentech) Dominates First-Line Biologic Use in Diabetic Retinopathy Despite Eylea's (Regeneron) Best Efforts to Secure Share in the Space, According to Spherix Global Insights
/PRNewswire/ -- Despite the availability of on-label products to treat diabetic retinopathy (DR), Genentechs off-label option, Avastin, is the predominant...
Vabysmo Genentech Genentech Lucentis National Institute Of Health While Eylea Realworld Dynamix Biologic New Starts
Source: prnewswire.com